The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,733.50
Bid: 1,732.50
Ask: 1,733.00
Change: 5.00 (0.29%)
Spread: 0.50 (0.029%)
Open: 1,733.00
High: 1,739.50
Low: 1,724.50
Prev. Close: 1,728.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Tuesday newspaper round-up: BRICs, Inflation, GlaxoSmithKline...

Tue, 18th Jan 2011 06:33

Goldman Sachs has issued a short-term alert on China and India as inflation rears its ugly head, advising clients to rotate into Wall Street and Old World bourses as a safer bet over coming months."We're not as tactically positive on the BRICs as we have been," said Tim Moe, the bank's chief Asia-Pacific strategist, referring to the quartet of Brazil, Russia, India, and China. "To be frank, we may have held on too long to our overweight position in China last year. We have decided that discretion is the better part of valour and have tactically reduced our weight. Asia is not in the sweet part of the cycle." the Telegraph reports.China has lent more money to other developing countries over the past two years than the World Bank, a stark indication of the scale of Beijing's economic reach and its drive to secure natural resources. China Development Bank and China Export-Import Bank signed loans of at least $110bn (£70bn) to other developing country governments and companies in 2009 and 2010, according to Financial Times research.Goldman Sachs has scrapped an offer to its wealthy clients in the US to participate in a $1.5bn investment in Facebook, dealing a blow to one of the most closely watched private financings for a US company in years. The offer will still be open to investors elsewhere but the bank said that the high level of publicity the plan had generated threatened to put it in breach of US securities laws, which are designed to limit the promotion of private share sales, the FT reports.Inflation is likely to jump to a two-year high today, as economists predict the headline rate will peak soon at more than 5% - raising further questions about whether the Bank of England should raise interest rates faster than expected. Such a move, which could come as early as May, would quickly add about £40 to the average monthly mortgage bill. David Cameron recently said the rate of inflation was "concerning", the Independent reports.European finance ministers have increased their support for a bigger rescue fund for debt-laden eurozone countries, but EU paymaster Germany said there was no rush and it could be March before a package of wider changes would be approved. A two-day monthly Ecofin meeting in Brussels, which started on Monday night, will focus on discussing a boost to the lending power of the European Financial Stability Facility (EFSF), the Telegraph reports.DE Shaw, one of the world's biggest hedge funds, has taken a near £100m short position in Barclays amid concern over the future health of the banking industry. The hedge fund, which has $21bn (£13bn) in assets under management, disclosed that it had built a 0.26% short position. The position is worth £97m after Barclays' shares closed at 306p on Monday, the Telegraph reports.GlaxoSmithKline admitted yesterday that its profits for the final three months of last year will be wiped out by legal costs relating to its Avandia diabetes drug, which has been linked to heart attacks and strokes in users. The company will record a £2.2bn legal charge as it settles further claims linked to the drug that was once its second-best-selling product ? and hundreds more American lawsuits are still in the pipeline, the Times reports.The new chief executive of a quango targeted for cuts has accepted a pay package about £61,000 smaller than his predecessor in a move that reduces his pay below that of the Prime Minister. Bill Galvin, who yesterday was promoted to be chief executive of The Pensions Regulator ? one of hundreds of quangos facing cuts ? will receive base pay of £138,000, which is £4,500 less than David Cameron. It represents a cut of about £39,000, or 22%, on the £175,000-179,000 base salary paid to his predecessor Tony Hobman, who left in May, the Times reports.BP's £10bn share swap with Russia's Rosneft could signal the end of its long-troubled relationship with Washington, according to leading shareholders. The landmark deal, formalised on Friday, also makes it more likely that the oil group will consider breaking itself up along geographical lines, several top investors said. BP could spin off a stronger Russian business and sell its North American division, either in part or as a whole, they said. While strengthening ties with the Kremlin carries political risks, shareholders said it could help to stabilise TNK-BP, BP's turbulent existing joint venture in Russia, over the longer term, the Times reports.
More News
17 Dec 2023 15:16

PRESS: GSK looks for deals in China as rebuilds relationship

(Alliance News) - The Financial Times on Sunday reported that GSK PLC is looking for some new deals in China.

Read more
15 Dec 2023 17:08

European shares end fifth week higher on rate-cut optimism

Barclays sees first ECB rate cut in April

*

Read more
15 Dec 2023 16:51

LONDON MARKET CLOSE: FTSE 100 underperforms as post-Fed rally cools

(Alliance News) - London's FTSE 100 ended lower on Friday, with profit-taking and some hawkish words from a US policymaker keeping equities in check at the end of a largely positive week for stocks.

Read more
15 Dec 2023 16:29

PRESS: GSK, Astra and AbbVie in US scrutiny over patents - Bloomberg

(Alliance News) - A US senator has accused AstraZeneca PLC, GSK PLC, AbbVie Inc and other drugmakers of "abusing" the patent system to send prices higher, Bloomberg reported on Thursday.

Read more
12 Dec 2023 10:08

AstraZeneca buys respiratory vaccine developer Icosavax in $1.1 bln deal

Dec 12 (Reuters) - AstraZeneca said on Tuesday it had agreed to buy respiratory syncytial virus (RSV) vaccine developer Icosavax in a deal valued at up to $1.1 billion.

Read more
12 Dec 2023 08:22

TOP NEWS: Japan accepts GSK's filing for respiratory disease vaccine

(Alliance News) - GSK PLC on Tuesday said Japan's Ministry of Health, Labour & Welfare has accepted its regulatory application for the extension of its respiratory syncytial virus vaccine, Arexvy, for adults aged 50-59.

Read more
12 Dec 2023 07:39

LONDON BRIEFING: UK unemployment unchanged at 4.2%; eyes on US CPI

(Alliance News) - Stocks in London are called to open higher, as investors digest the latest UK unemployment data, before turning their heads to US inflation.

Read more
12 Dec 2023 07:24

GSK seeks to extend RSV vaccine approval in Japan

(Sharecast News) - GSK announced on Tuesday that Japan's Ministry of Health, Labour and Welfare (MHLW) has accepted its regulatory application for the extension of the indication of its RSV vaccine to include adults aged 50- to 59 at an increased risk of contracting the disease.

Read more
11 Dec 2023 08:28

GSK drug gets EU marketing backing for form of endometrial cancer

(Alliance News) - GSK PLC on Monday said it won EU backing for its Jemperli drug in tandem with chemotherapy to treat a form of endometrial cancer.

Read more
11 Dec 2023 07:41

LONDON BRIEFING: GSK drug gets EU endorsement; Begbies backs outlook

(Alliance News) - London's FTSE 100 is called to open a touch lower on Monday, kicking off the week with some slight trepidation after Friday's hotter-than-expected US jobs report which offered the dollar some respite.

Read more
11 Dec 2023 07:23

GSK endometrial cancer treatment gets Europe authorisation

(Sharecast News) - GSK announced on Monday that the European Commission has granted marketing authorisation for 'Jemperli', or dostarlimab, in combination with chemotherapy for certain endometrial cancers.

Read more
7 Dec 2023 12:54

THG backer Kelso pushes for demerger to trim "inherent" valuation gap

(Alliance News) - THG PLC investor Kelso Group Holdings PLC on Thursday reiterated its call for a demerger, which the shareholder believes will help close the "disparity" between the e-commerce firm's share price and its true value.

Read more
5 Dec 2023 10:02

LONDON BROKER RATINGS: Goldman lifts Landsec and British Land

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
27 Nov 2023 09:00

GSK announces positive results from Blenrep phase 3 blood cancer trial

(Alliance News) - GSK PLC on Monday said a phase 3 trial of belantamab mafodotin as a multiple myeloma treatment has produced positive headline results.

Read more
27 Nov 2023 08:02

GSK receives 'positive' headline results from phase III trial

(Sharecast News) - Drugmaker GSK announced on Monday that it had received positive headline results from a planned interim efficacy analysis from a phase III trial evaluating its elantamab mafodotin asset.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.